EVERSANA™ expands pharmaceutical training and digital engagement capabilities with acquisition of Alkemy Partners

News provided by

Sep 09, 2020, 08:59 ET

CHICAGO, Sept. 9, 2020 /PRNewswire/ -- EVERSANA™, the leading provider of commercial services to the life science industry, today announced the acquisition of Alkemy Partners, a full-service field learning and development company committed to solving market access, sales and clinical engagement through training, content creation and digital solutions. The acquisition of the New Hampshire-based company expands EVERSANA's fully integrated, next-generation commercial services platform designed to solve global pricing, access, reimbursement, adherence and product delivery challenges for pre-launch and in-market therapies and medical devices.

"Pharmaceutical companies are navigating the realities of a new world. Now more than ever, front-line clinical, market access, and field commercial teams need robust training partners offering innovative methods that can be delivered remotely, not traditional strategies," said Jim Lang, CEO, EVERSANA. "This marks a critical step as we reimagine the commercialization of much-needed therapies. We're advancing the measures needed to effectively engage all stakeholders in today's world and leveraging data and analytics to optimize field outreach in real time to ensure appropriate patient utilization."

With Alkemy, EVERSANA bolsters its field solutions and training services with clinical, commercial and market access training and technology solutions. These solutions include medical writing, training facilitation, leadership development, sales force effectiveness, programmatic consulting, multimedia development, creative communication planning, and subject-matter leadership across complex therapeutic areas, including deep oncology expertise.

Alkemy Partners is widely recognized as a leader in the learning and development space, as well as a top company to work for, having been named to Inc. magazine's Fastest-Growing Companies in 2019 and 2020.

"We're thrilled to join a growing, global company like EVERSANA that shares our commitment to impact patient lives," said Jim Kaveney, founder and president, Alkemy Partners. "We were looking for the right partner to help expand our growth, and through several recent projects with EVERSANA and relationships with their leadership team, it became clear that now is the ideal time to join forces for both our employees and clients."

The company's employees will become part of the EVERSANA team immediately. Jim Kaveney, Lisa Stafford and additional members of the Alkemy Partners leadership team will report to Peter Marchesini, president, Field Solutions, EVERSANA.

Financial details of the acquisition are not being disclosed.

About EVERSANA™

EVERSANA™ is the leading independent provider of global services to the life science industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life science solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.

CONTACT:
Sarah Zwicky
[email protected]
414.434.4691

SOURCE Eversana